Bristol-Myers’ Opdivo-Yervoy sBLA for NSCLC Accepted by FDA
Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA 1sBLA for the Opdivo-Yervoy combo for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.
News story posted on 2020-01-16T16:32:00.0000000Z